John J. Piwinski, PhD
John J. Piwinski has extensive expertise in small molecule drug discovery with over 30 years of experience in medicinal chemistry. During his career, he oversaw discovery programs in chemistry from project initiation to delivery of candidates for clinical development. He received his B.S. degree in Chemistry and Biochemistry from the State University of New York at Stony Brook in 1976 and his Ph.D. in Organic Chemistry from Yale University in 1980.
He then joined Revlon Health Care as a Senior Scientist working in the cardiovascular diseases area. In 1983 he moved to Schering-Plough where he worked in the respiratory diseases group. At Schering he held positions of increasing responsibility and eventually oversaw Chemical Research as Vice President from 1999 to 2003 and Group Vice President from 2004 to 2008. In this position he was responsible for overseeing drug discovery in chemistry in Kenilworth, New Jersey in the areas of respiratory, inflammation, cardiovascular, CNS, oncology and infectious diseases. In 2008 he became the Site Head and Group Vice President of Schering-Plough’s Cambridge, Massachusetts site. Research at the site focused on medicinal chemistry, affinity-based screening and optimization, bioNMR, protein science and biologics. Merck acquired Schering-Plough in 2009 and continued to operate the Cambridge site until the end of 2010.
He is currently Principal of JJPiwinski Pharma Consulting, LLC in Lebanon, New Jersey and consults in the areas of medicinal chemistry and drug discovery, including small
molecule lead discovery and optimization. In this role he has consulted for numerous
companies, which included conducting program reviews, due diligences and patent work. He has presented numerous talks at scientific meetings and has approximately 150 published research papers, abstracts and approved U.S. patents. He has been a member of the American Chemical Society since 1977, serves on two NIH Drug Development Program Review Panels, and is also a member for the Institute of Chemical Biology & Drug Discovery Advisory Board at Stony Brook University. In recognition of his accomplishments, he received the North Jersey American Chemical Society (NJACS) Lifetime Achievement Award in 2013.